Actinium Pharmaceuticals, Inc. (ATNM)
1.075
+0.02
(+2.38%)
USD |
NYAM |
Aug 25, 10:02
Actinium Pharmaceuticals Gross Profit Margin (Quarterly) : 98.77% for June 30, 2026
Gross Profit Margin (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Gross Profit Margin (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 98.77% |
| March 31, 2026 | |
| December 31, 2025 | |
| September 30, 2025 | -128.9% |
| June 30, 2025 | |
| March 31, 2025 | |
| December 31, 2024 | |
| September 30, 2024 | |
| June 30, 2024 | |
| March 31, 2024 | |
| December 31, 2023 | -145.7% |
| Date | Value |
|---|---|
| September 30, 2023 | |
| June 30, 2023 | |
| March 31, 2023 | |
| December 31, 2022 | |
| September 30, 2022 | -391.1% |
| June 30, 2022 | -300.0% |
| March 31, 2022 | 85.43% |
| December 31, 2021 | -495.7% |
| September 30, 2021 | 0.00% |
| June 30, 2021 | 0.00% |
| March 31, 2021 | 0.00% |
Gross Profit Margin Definition
Gross Profit Margin is calculated using Gross Profit/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into gross profit and doing this by keeping cost of goods sold low. An analyst looking at gross profit margin might look for a higher gross profit margin relative to other comparable companies as well as a gross profit margin that is growing.
Gross Profit Margin (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Gross Profit Margin (Quarterly) Benchmarks
| ACADIA Pharmaceuticals, Inc. | 90.81% |
| Alnylam Pharmaceuticals, Inc. | 76.88% |
| Anika Therapeutics, Inc. | 65.15% |
| Savara, Inc. | -- |
| Vericel Corp. | 72.82% |
Gross Profit Margin (Quarterly) Related Metrics
| Return on Equity | 77.20% |
| Return on Assets | 22.00% |
| Return on Invested Capital | 70.48% |
| Profit Margin (Quarterly) | 79.72% |
| Operating Margin (Quarterly) | 78.76% |
| Return on Net Operating Assets | 548.7% |